321 related articles for article (PubMed ID: 11938457)
1. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
Mautino MR; Morgan RA
Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
Mautino MR; Keiser N; Morgan RA
J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
[TBL] [Abstract][Full Text] [Related]
3. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.
Plavec I; Agarwal M; Ho KE; Pineda M; Auten J; Baker J; Matsuzaki H; Escaich S; Bonyhadi M; Böhnlein E
Gene Ther; 1997 Feb; 4(2):128-39. PubMed ID: 9081703
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.
Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP
Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HIV-1 replication by combined expression of gag dominant negative mutant and a human ribonuclease in a tightly controlled HIV-1 inducible vector.
Cara A; Rybak SM; Newton DL; Crowley R; Rottschafer SE; Reitz MS; Gusella GL
Gene Ther; 1998 Jan; 5(1):65-75. PubMed ID: 9536266
[TBL] [Abstract][Full Text] [Related]
6. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
[TBL] [Abstract][Full Text] [Related]
7. Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication.
Klimatcheva E; Planelles V; Day SL; Fulreader F; Renda MJ; Rosenblatt J
Mol Ther; 2001 Jun; 3(6):928-39. PubMed ID: 11407907
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
[TBL] [Abstract][Full Text] [Related]
9. Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication.
Caputo A; Rossi C; Bozzini R; Betti M; Grossi MP; Barbanti-Brodano G; Balboni PG
Gene Ther; 1997 Apr; 4(4):288-95. PubMed ID: 9176513
[TBL] [Abstract][Full Text] [Related]
10. Intracellular inhibition of HIV-1 replication using a dual protein- and RNA-based strategy.
Duan L; Zhu M; Ozaki I; Zhang H; Wei DL; Pomerantz RJ
Gene Ther; 1997 Jun; 4(6):533-43. PubMed ID: 9231069
[TBL] [Abstract][Full Text] [Related]
11. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
Peng H; Callison D; Li P; Burrell C
Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
[TBL] [Abstract][Full Text] [Related]
12. High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector.
Fraisier C; Irvine A; Wrighton C; Craig R; Dzierzak E
Gene Ther; 1998 Dec; 5(12):1665-76. PubMed ID: 10023446
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of HIV-1 by a double transdominant fusion gene.
Aguilar-Cordova E; Chinen J; Donehower LA; Harper JW; Rice AP; Butel JS; Belmont JW
Gene Ther; 1995 May; 2(3):181-6. PubMed ID: 7614248
[TBL] [Abstract][Full Text] [Related]
14. Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T cells.
Liu J; Woffendin C; Yang ZY; Nabel GJ
Gene Ther; 1994 Jan; 1(1):32-7. PubMed ID: 7584057
[TBL] [Abstract][Full Text] [Related]
15. Regulation of HIV-1 envelope protein synthesis by Tat and Rev in 293 cells.
Natarajan V; Radjendirane V; Salzman NP
Virology; 1993 Sep; 196(1):122-9. PubMed ID: 8356789
[TBL] [Abstract][Full Text] [Related]
16. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.
Chang LJ; Liu X; He J
Gene Ther; 2005 Jul; 12(14):1133-44. PubMed ID: 15750613
[TBL] [Abstract][Full Text] [Related]
17. Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy.
Junker U; Böhnlein E; Veres G
Gene Ther; 1995 Nov; 2(9):639-46. PubMed ID: 8548553
[TBL] [Abstract][Full Text] [Related]
18. Analysis of trans-dominant mutants of the HIV type 1 Rev protein for their ability to inhibit Rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics.
Ragheb JA; Bressler P; Daucher M; Chiang L; Chuah MK; VandenDriessche T; Morgan RA
AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1343-53. PubMed ID: 8573391
[TBL] [Abstract][Full Text] [Related]
19. Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA.
Mautino MR; Morgan RA
Hum Gene Ther; 2002 Jun; 13(9):1027-37. PubMed ID: 12067436
[TBL] [Abstract][Full Text] [Related]
20. Improved titers of HIV-based lentiviral vectors using the SRV-1 constitutive transport element.
Mautino MR; Keiser N; Morgan RA
Gene Ther; 2000 Aug; 7(16):1421-4. PubMed ID: 10981670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
